Fulcrum Therapeutics Inc (NASDAQ: FULC) is -55.48% lower on its value in year-to-date trading and has touched a low of $2.87 and a high of $13.70 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The FULC stock was last observed hovering at around $3.32 in the last trading session, with the day’s loss setting it -0.31%.
Currently trading at $3.01, the stock is -10.05% and -19.92% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.28 million and changing -9.49% at the moment leaves the stock -58.65% off its SMA200. FULC registered -28.11% loss for a year compared to 6-month loss of -60.20%. The firm has a 50-day simple moving average (SMA 50) of $3.7524 and a 200-day simple moving average (SMA200) of $7.267775.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -15.35% gain in the last 1 month and extending the period to 3 months gives it a -67.83%, and is -13.90% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.22% over the week and 5.98% over the month.
Fulcrum Therapeutics Inc (FULC) has around 76 employees, a market worth around $146.71M and $80.87M in sales. Profit margin for the company is -22.15%. Distance from 52-week low is 4.89% and -78.07% from its 52-week high. The company has generated returns on investments over the last 12 months (-6.78%).
The EPS is expected to grow by 89.15% this year, but quarterly earnings will post 2,752.05% year-over-year. Quarterly sales are estimated to shrink -100.00% in year-over-year returns.
Fulcrum Therapeutics Inc (FULC) Top Institutional Holders
165.0 institutions hold shares in Fulcrum Therapeutics Inc (FULC), with institutional investors hold 91.17% of the company’s shares. The shares outstanding are 61.92M, and float is at 54.18M with Short Float at 9.17%. Institutions hold 89.70% of the Float.
The top institutional shareholder in the company is RA CAPITAL MANAGEMENT, L.P. with over 11.61 million shares valued at $71.98 million. The investor’s holdings represent 18.7302% of the FULC Shares outstanding. As of 2024-06-30, the second largest holder is RTW INVESTMENTS, LP with 5.85 million shares valued at $36.24 million to account for 9.4314 of the shares outstanding. The other top investors are FMR LLC which holds 5.33 million shares representing 8.5989% and valued at over $33.05 million, while BLACKROCK INC. holds 7.7415 of the shares totaling 4.8 million with a market value of $29.75 million.
Fulcrum Therapeutics Inc (FULC) Insider Activity
The most recent transaction is an insider sale by Tourangeau Greg, the company’s Principal Accounting Officer. SEC filings show that Tourangeau Greg sold 236 shares of the company’s common stock on May 07 ’24 at a price of $7.76 per share for a total of $1831.0. Following the sale, the insider now owns 11571.0 shares.
Fulcrum Therapeutics Inc disclosed in a document filed with the SEC on Mar 08 ’24 that Tourangeau Greg (Vice President, Finance) sold a total of 4,884 shares of the company’s common stock. The trade occurred on Mar 08 ’24 and was made at $11.72 per share for $57219.0. Following the transaction, the insider now directly holds 11807.0 shares of the FULC stock.
Still, SEC filings show that on Mar 04 ’24, Sapir Alex () acquired 43,360 shares at an average price of $11.35 for $0.49 million. The insider now directly holds 43,360 shares of Fulcrum Therapeutics Inc (FULC).
